EU’s Push for Vaccine Supplies Gets Help From Bayer Agreement
- Bayer to start producing CureVac’s shot at end of year
- CureVac vaccine is still advancing through clinical tests
This article is for subscribers only.
Bayer AG agreed to produce CureVac NV’s experimental coronavirus vaccine to boost the rollout of a promising shot as European Union governments scramble for additional supplies to spur a plodding campaign.
The move won’t have an immediate effect, though it’s at least some good news for Europe after a week of chaos surrounding its program. The controversy escalated after the European Commission threatened curbs on vaccine exports -- sparking global anger -- in response to news that AstraZeneca Plc would miss delivery targets.